Brought to you by 
Takeda's final offer for Shire PLC stands; £46bn merger creates new top ten pharmaco
09 Jan 2019
Executive Summary
Following over a month of back and forth and four rejected offers, Shire PLC finally accepted a merger bid from Takeda Pharmaceutical Co. Ltd. The deal, which values Shire at about £46bn ($61.2bn; enterprise value of close to $80bn, including net debt), consists of $30.33 in cash and 0.839 of a new Takeda share or 1.678 Takeda ADSs for each outstanding Shire share, for an implied value per Shire share of £49.01 and a total of 44% cash and 56% equity.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda's final offer for Shire PLC stands; £46bn merger creates new top ten pharmaco
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice